An innovative combination of cypropheptadine and prazosin for the treatment of alcohol use disorder: a double-blind, randomised, parallel-group, three-arm, multicentre, placebo-controlled phase 2 trial
Introduction Animal studies have shown that the simultaneous blockade of α1b-noradrenergic receptors and 5HT2A-serotonergic receptors strongly decreases alcohol intake. In addition, recent clinical studies have indicated that the selective α1b antagonist prazosin could be effective on alcohol use r...
Main Authors: | H.-J. Aubin, A. Puech |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822003467/type/journal_article |
Similar Items
-
Estimation of treatment allocation in a randomised, double-blinded, placebo-controlled trial
by: Milica Popovic, et al.
Published: (2019-07-01) -
Heterogeneity in pragmatic randomised trials: sources and management
by: Bruno Giraudeau, et al.
Published: (2022-10-01) -
REmote preconditioning for Protection Against Ischaemia–Reperfusion in renal transplantation (REPAIR): a multicentre, multinational, double-blind, factorial designed randomised controlled trial
by: Raymond MacAllister, et al.
Published: (2015-05-01) -
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
by: James H. McMahon, et al.
Published: (2022-12-01) -
Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial
by: Kyungha Min, et al.
Published: (2023-08-01)